Novartis says 'completely committed' to Sandoz, not planning split-off

Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan plans to split the unit off.